Platform for MS care was finalist for Innovation by Design Awards
Octave Bioscience was selected as a finalist in this year’s Innovation by Design Awards in recognition of the platform…
Articles by Andrea Lobo, PhD
Experimental MS therapy NB-4746 to be tested in healthy volunteers
Nura Bio has launched a Phase 1 clinical trial evaluating NB-4746, its investigational treatment for multiple sclerosis (MS)…
Neuro Night event to raise funds for neurological care, research
Neuro Night, a philanthropic event set for October in Scottsdale, Arizona, is raising funds for the Barrow Neurological Institute…
Mavenclad lowers relapse rates, helps RRMS patients reach NEDA-3
Treatment with Mavenclad (cladribine), an approved short-course oral therapy for relapsing forms of multiple sclerosis (MS), significantly reduced…
Web-based wellness program improves life quality, lowers fatigue
A web-based wellness intervention program that educated multiple sclerosis (MS) patients on dietary plans, stress management, sleep, and exercise…
MS raises person’s risk of dementia and Alzheimer’s, study suggests
People with multiple sclerosis (MS) are at a greater risk than the general public of developing any type of…
CPT code issued for MRI brain scan software by Icometrix
Icometrix‘s quantification software for brain MRI scans has received a Current Procedural Terminology (CPT) III code, a temporary code…
Neurologist Xavier Montalban wins 2023 Charcot Award for research
The director of the Multiple Sclerosis Center of Catalonia (CEMCAT) has been recognized with the 2023 Charcot Award, a…
Potential blood biomarker of Gilenya response found in MS patients
A microRNA called miR-548a-3p, a small molecule important for regulation of gene activity, may help to identify people with…
Canadian TV airs award-winning documentary on man’s MS journey
As part of last week’s World MS Day, a documentary about the life of Mathew Embry, a multiple sclerosis…
CMSC updates core values to more actively address inequalities in care
In an effort to improve access to medical care for all people with multiple sclerosis (MS), the Consortium…
Candidate therapy MRT-6160 chosen for MS, other autoimmune diseases
Monte Rosa Therapeutics has selected MRT-6160, its second candidate for development, for treating multiple sclerosis (MS) and several…
Ocrevus reduces B-cells’ diversity, but not T-cells’, in relapsing MS
Long-term treatment with Ocrevus (ocrelizumab) doesn’t change the diversity of T-cells — those needed to mount effective immune responses…
US patent secured for experimental LPX-TI641 for autoimmune diseases
LAPIX Therapeutics has secured a new U.S. patent covering the use of its experimental oral therapy LPX-TI641 as a…
Fenebrutinib significantly reduced brain lesions in relapsing MS: Trial
Genentech‘s investigational BTK inhibitor fenebrutinib significantly reduced the number of new brain lesions and showed no new safety…
Briumvi’s permanent J-code will aid reimbursement for MS patients
The recently approved CD20 inhibitor Briumvi (ublituximab-xiiy) has received a permanent insurance reimbursement code that will simplify claims submissions…
Aidaptus auto-injector wins Red Dot award for product design
Owen Mumford‘s Aidaptus auto-injector, which lets a wide range of under-the-skin medications to be administered, has won a Red…
Janssen acquires rights to PIPE-307, potential myelin restoring therapy
Pipeline Therapeutics is collaborating with a branch of Janssen Pharmaceuticals to advance PIPE-307, a potential oral treatment of…
Yoga better than physical therapy at improving MS quality of life: Study
A three-month yoga program was significantly better than physical therapy at improving quality of life in people with multiple…
Cariloop partners with Walgreens to support MS patients, caregivers
Cariloop has teamed up with Walgreens to provide support services at select neurology-specialty pharmacies to people with multiple…
Vaccine against Epstein-Barr virus may enter clinical trial next year
EBViously announced that it has developed a candidate vaccine against the Epstein-Barr virus and plans to bring it into…
Early treatment with Mavenclad, antibodies eased highly active MS
Early treatment with Mavenclad (cladribine) or monoclonal antibodies is more likely to control symptoms in people with highly active…
Quitting smoking or moving to snuff may help slow MS progression
Smoking and exposure to secondhand smoke are both associated with significantly faster disease progression in people with multiple sclerosis…
Fujirebio launched 2 automated tests to quantify key protein in blood, CSF
Fujirebio has launched two fully automated laboratory tests to measure levels of the neurofilament light chain (NfL) protein, a…
Drinking coffee and tea may protect against MS, study says
People who drink black and green tea, coffee, and nonalcoholic beer may be significantly less likely to develop multiple…
Sleep disorders in MS women may be factor in cognitive decline: Study
Note: This story was updated March 29, 2023, to correct that cognitive function was assessed via questions about memory and…
Adherence to high-quality MS diet may help ease depression in patients
Adherence to a high-quality diet may help alleviate symptoms of depression in people with multiple sclerosis (MS), a…
Greater MS disability reported in patients with COVID-19 infection
Infection with the virus that causes COVID-19 significantly accelerates neurological disability in people with multiple sclerosis (MS), at least…
WHO asked to add 3 MS treatments to its list of ‘essential medicines’
Aiming to promote equitable access to multiple sclerosis (MS) treatments worldwide, an international MS alliance is asking that three disease-modifying therapies…
MS Australia supporting work into how diet might affect pediatric MS
MS Australia is funding a study by researchers at Curtin University into how diet might affect multiple sclerosis (MS)…